The effect of cholinergic enhancement on brain activation in Parkinson*s disease patients with visual hallucinations using fMRI.

The effect of cholinergic enhancement on brain activation in Parkinson*s disease patients with visual hallucinations using fMRI. - Cholinergic enhancement in PD patients with VH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33228

Enrollment

Registered

2009-07-20

Start date

2009-06-24

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease visual hallucinations

Interventions

fMRI will be performed in two scanning sessions during which subjects watch a dynamic presentation of images popping out of noise either after placebo or after administration of rivastigmine. Severa

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - PD according to UK brain bank criteria - At least weekly VH - MMSE>24 - FAB>=12

Exclusion criteria

Exclusion criteria: - Instable internal or psychiatric disease - Visual acuity

Design outcomes

Primary

Measure	Time frame
Primary outcome: cerebral activation change after administration of rivastigmine, compared to placebo, using fMRI	—

Secondary

Measure	Time frame
Secondary outcomes: Clinical effect of rivastigmine on cognition and extent of VH. Correlation between clinical effect and cerebral activation effect of rivastigmine.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)